share_log

Earnings Call Summary | Certara(CERT.US) Q1 2024 Earnings Conference

Earnings Call Summary | Certara(CERT.US) Q1 2024 Earnings Conference

業績電話會議摘要 | Certara (CERT.US) 2024 年第一季度業績會議
富途資訊 ·  05/08 16:59  · 電話會議

The following is a summary of the Certara, Inc. (CERT) Q1 2024 Earnings Call Transcript:

以下是Certara, Inc.(CERT)2024年第一季度業績電話會議記錄摘要:

Financial Performance:

財務業績:

  • Certara reported Q1 2024 total revenue of $96.7 million, a reported growth of 7% and 6% in constant currency.

  • Software revenue was $39.3 million, indicating 19% reported growth and 18% in constant currency.

  • The technology-driven services segment reported stable year-over-year revenue at $57.3 million.

  • The company recorded a net loss of $4.7 million in Q1 2024, compared to $1.4 million net income in Q1 2023.

  • Adjusted EBITDA was $29.1 million for Q1 2024.

  • The company anticipated its FY 2024 total revenue to range from $385 million to $400 million, with an adjusted EPS between $0.41 to $0.46 per share.

  • Certara報告稱,2024年第一季度總收入爲9,670萬美元,按固定貨幣計算增長了7%和6%。

  • 軟件收入爲3,930萬美元,表明增長了19%,按固定貨幣計算增長了18%。

  • 技術驅動的服務板塊報告稱,同比收入穩定,爲5,730萬美元。

  • 該公司在2024年第一季度錄得淨虧損470萬美元,而2023年第一季度的淨收入爲140萬美元。

  • 2024年第一季度調整後的息稅折舊攤銷前利潤爲2910萬美元。

  • 該公司預計其2024財年的總收入將在3.85億美元至4億美元之間,調整後的每股收益在0.41美元至0.46美元之間。

Business Progress:

業務進展:

  • Certara introduced Certara Cloud that currently caters to 15 of the top 30 biopharmaceutical companies.

  • It also planned to launch the next version of CoAuthor, an AI and machine learning-based regulatory writing tool.

  • The company invested heavily in improving commercial infrastructure and expanding biosimulation software capabilities.

  • The restructuring of its commercial organization and integration of AI in software offerings have positively impacted sales and marketing.

  • Expectations for an increase in bookings from recently acquired companies are projected to support revenue growth for the rest of the year.

  • Certara推出了Certara Cloud,目前爲排名前30位的生物製藥公司中的15家提供服務。

  • 它還計劃推出下一版本的CoAuthor,這是一款基於人工智能和機器學習的監管寫作工具。

  • 該公司在改善商業基礎設施和擴大生物仿真軟件能力方面進行了大量投資。

  • 其商業組織的重組以及將人工智能整合到軟件產品中,對銷售和營銷產生了積極影響。

  • 預計最近收購的公司預訂量將增加,這將支持今年剩餘時間的收入增長。

More details: Certara IR

更多詳情: Certara IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論